Gilbert Lynn Marks - 20 Feb 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks
Issuer symbol
ANTX
Transactions as of
20 Feb 2026
Net transactions value
$0
Form type
4
Filing time
23 Feb 2026, 16:29:59 UTC
Previous filing
14 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Marks Gilbert Lynn Director C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK /s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks 23 Feb 2026 0001916940

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (Right to Buy) Award $0 +20,400 $0.000000 20,400 20 Feb 2026 Common Stock 20,400 $1.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.